Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

ABSTRACT:

Objectives

The primary objective of this study was to characterize the pharmacokinetics of etonogestrel (ENG) released from a contraceptive implant in Ugandan women living with HIV who were receiving efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART), compared with ART-naive women over 24 weeks.

Design

Nonrandomized, parallel-group study with three arms: ART-naive, NVP, or EFV-based ART (N = 20/group).

Methods

Sparse pharmacokinetic sampling of ENG, NVP, or EFV were performed at screening, entry, and then 1, 4, 12, and 24-week postimplant insertion. The primary endpoint was ENG concentrations at week 24, compared between the ART-naive group and each ART group, using geometric mean ratio (GMR) with 90% confidence intervals.

Results

Sixty part

SUBMITTER: Chappell CA 

PROVIDER: S-EPMC5578871 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature